Expanding the Treatment Possibilities in SCCHN: What Role Do Cancer Immunotherapies Have?

Access Course


884823.jpg?interpolation=lanczos-none&resize=300:225Drs Haddad, Bauman, and Mehra discuss the latest data as well as practicalities of using immunotherapy in SCCHN.

This activity is intended for oncologists, surgeons, and pathologists.

The goal of this activity is to discuss the recent advances in the use of immunotherapy for head and neck cancer.




Approximate Time to Complete: 30 minutes


Credit Available: Nov. 29, 2017 - Nov. 29, 2018


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the guideline-recommended care in the management of recurrent/metastatic squamous cell carcinoma of the head and neck
  • Have increased knowledge regarding the emerging clinical trial data on the use of immune checkpoint inhibitors alone or in combination in the management of squamous cell carcinoma of the head and neck
Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)™: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50